Meeting Coverage

Review highlights emerging psoriasis therapies, including IL-21, Snora73, gut microbiome, and natural treatments, offering new patient-centered options.

The 2025 AAD Meeting features key psoriasis sessions on therapies, JAK inhibitors, obesity links, patient care gaps, and cutting-edge treatment advances.

Geeta Yadav, MD, and colleagues used a Canadian Delphi consensus to produce guidelines to optimize psoriasis management in patients with skin of color.

Highlights from SABCS 2024, male breast cancer, FISH and NGS Use in HER2, and More

In a recent session at the 2025 Winter Clinical meeting in Hawaii, presenters shared how dermatologists can add or alter treatments to improve response.

A study at ASH 2024 found that early progression of disease in mantle cell lymphoma significantly worsens survival, indicating the need for a more nuanced approach to risk stratification.

Research published in JAMA Dermatology indicated that home-based phototherapy was as effective as office-based phototherapy for patients with psoriasis.

Findings from the VISIBLE trial will help address gaps in psoriasis care for patients with skin of color and inform best practices to drive inclusive research.

A curated roundup of what happened at ASH 2024, focused on CLL/SLL – treatment updates, improving QOL, and novel agents.

A study exploring the link between disorders of gut-brain interaction and fibromyalgia severity offers insights into managing this complex condition.

MCL patients with secondary malignancies have significantly shorter survival, particularly due to skin cancers and secondary leukemia.

The ASH Research Collaborative developed the COSMIC study to address the risks severe COVID-19 complications pose to patients with multiple myeloma.

The TELEPROM Psoriasis study highlights how telepharmacy and patient-reported outcomes improve the quality of life for patients with moderate-to-severe psoriasis.

Monoclonal antibody delayed progression to MM, improved PFS, ORR, and OS, and was well tolerated in high-risk SMM, supporting early intervention over monitoring.

Liso-cel shows durable efficacy in R/R CLL/SLL, with extended OS of 43.2 months, high uMRD rates, and consistent safety after nearly two years of follow-up.